je.st
news
Tag: pharmaceuticals
X-Chem And Navitor Pharmaceuticals Enter Into License Agreement On Novel Small Molecules Targeting mTORC1 Activation
2015-04-01 08:58:00| drugdiscoveryonline Home Page
X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, recently announced that Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling, exercised its option to obtain an exclusive license to a series of small molecules targeting the activation of mTORC1, a key protein complex that orchestrates nutrient-mediated cellular metabolism and growth
Tags: enter
small
agreement
license
Peregrine Pharmaceuticals Announces Promising Bavituximab Phase I...
2015-03-31 22:46:43| Biotech - Topix.net
Peregrine Pharmaceuticals , today announced the peer-reviewed publication of clinical data from a Phase I investigator-sponsored trial evaluating the company's lead investigational immunotherapy bavituximab plus paclitaxel therapy in patients with HER2-negative metastatic breast cancer. The manuscript details the results of the Phase I trial showing that the combination produced an objective tumor response in 85% of patients, including 15% of these patients achieving a complete response, measured in accordance with Response Evaluation Criteria In Solid Tumors criteria.
Tags: phase
announces
promising
pharmaceuticals
Ligand Pharmaceuticals: Biotech's Jack Of All Trades
2015-03-26 00:46:06| Biotech - Topix.net
"We do early-stage development, and we aim to partner early," said Matt Foehr, president and chief operating officer. "We keep a flat operating structure, and we enjoy royalties on the back."
Tags: jack
trades
pharmaceuticals
ligand
Conatus Pharmaceuticals and BioReliance Present Key Emricasan...
2015-03-23 22:00:37| Chemicals - Topix.net
Conatus Pharmaceuticals Inc. and its research collaborator BioReliance, Sigma-Aldrich Corporation's biologics and early-development services business, are presenting a poster today at the 54th Annual Meeting of the Society of Toxicology . The poster, entitled "Carcinogenicity Assessment of the Pan-Caspase Inhibitor, Emricasan, in Tg.rasH2 Mice," will be available for viewing in the Exhibit Hall of the San Diego Convention Center today, Monday, March 23, 2015, from 1:00 p.m. to 4:30 p.m. PT,and the authors will be available for discussion at the poster from 1:00 p.m. to 2:45 p.m. PT.
Tags: present
key
pharmaceuticals
present key
Progenics Pharmaceuticals Sets Fourth Quarter and Year End 2014 Financial Results Call for March 16
2015-03-09 17:47:47| Biotech - Topix.net
Progenics Pharmaceuticals, Inc., , an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review fourth quarter and year end 2014 financial results on Monday, March 16, at 8:30 a.m. ET. To participate, please dial 250-8889 or 545-0001 and reference conference ID 89741044.
Sites : [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] next »